Biogen Eisai Agreement

As such, BAN2401 has the potential to have an immunomodulatory effect capable of suppressing disease progression. Biogen has approved Neurimmune`s aducanumab under a joint development and licensing agreement. Since October 2017, Biogen and Eisai have been collaborating on the development and commercialization of aducanumab worldwide. Eisai takes advantage of the experience gained in the development and commercialization of a treatment for Alzheimer`s disease and wants to create the “Eisai Dementia Platform”. .

Responses are currently closed, but you can trackback from your own site.

Comments are closed.